Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy
Status:
Terminated
Trial end date:
2020-04-21
Target enrollment:
Participant gender:
Summary
ALMERA is a randomized, phase II, open label study in patients with locally advanced
non-small cell lung cancer (NSCLC) which will compare standard radiotherapy plus concurrent
chemotherapy with or without consolidation versus the same treatment plus concurrent
Metformin continuing for 12 months. Metformin is a well tolerated and inexpensive drug that
has the potential to improve cancer patient outcomes.